June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Real-world outcomes of Ranibizumab treatment for Diabetic Macular Oedema
Author Affiliations & Notes
  • Namritha Valerie Patrao
    NIHR Moorfields Biomedical Research Centre, London, United Kingdom
  • Sheelah Antao
    NIHR Moorfields Biomedical Research Centre, London, United Kingdom
  • Dawn A Sim
    NIHR Moorfields Biomedical Research Centre, London, United Kingdom
  • Sobha Sivaprasad
    NIHR Moorfields Biomedical Research Centre, London, United Kingdom
  • Richard Andrews
    NIHR Moorfields Biomedical Research Centre, London, United Kingdom
  • Robin Hamilton
    NIHR Moorfields Biomedical Research Centre, London, United Kingdom
  • Catherine A Egan
    NIHR Moorfields Biomedical Research Centre, London, United Kingdom
  • Adnan Tufail
    NIHR Moorfields Biomedical Research Centre, London, United Kingdom
  • Philip G Hykin
    NIHR Moorfields Biomedical Research Centre, London, United Kingdom
  • Ranjan Rajendram
    NIHR Moorfields Biomedical Research Centre, London, United Kingdom
  • Footnotes
    Commercial Relationships Namritha Patrao, None; Sheelah Antao, None; Dawn Sim, None; Sobha Sivaprasad, Allergan (F), Allergan (R), Bayer (F), Bayer (R), Novartis (F), Novartis (R), Roche (F), Roche (R); Richard Andrews, None; Robin Hamilton, Alcon (F), Allergan (F), Bayer (F), Bayer (R), Ellex (F), Ellex (R), Novartis (F), Novartis (R); Catherine Egan, Allergan (C), Novartis (F); Adnan Tufail, Allergan (F), Allergan (R), Bayer (F), Bayer (R), Novartis (F), Novartis (R), Roche (F), Roche (R); Philip Hykin, Allergan (F), Allergan (R), Bayer (F), Bayer (R), Novartis (F), Novartis (R); Ranjan Rajendram, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3148. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Namritha Valerie Patrao, Sheelah Antao, Dawn A Sim, Sobha Sivaprasad, Richard Andrews, Robin Hamilton, Catherine A Egan, Adnan Tufail, Philip G Hykin, Ranjan Rajendram; Real-world outcomes of Ranibizumab treatment for Diabetic Macular Oedema. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3148.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate real-world visual acuity (VA), clinical and Spectral Domain Optical Coherent Tomography (OCT) outcomes of intravitreal Ranibizumab therapy for Diabetic Macular Oedema (DMO) in a National Health Service (NHS) population.

Methods: 225 eyes of 178 patients diagnosed with centre-involving DMO and VA ≤ 79 ETDRS letters with central retinal thickness (CRT) ≥400µm on OCT and a foveal avascular zone greatest linear diameter ≤1500um on fundus fluorescein angiography initiated on a loading phase of 3 intravitreal Ranibizumab injections and who had at least 6 months follow up were reviewed. The treatment regimen subsequently included monthly reviews and PRN retreatment.<br /> <br /> Baseline characteristics, VA, number of injections, OCT central retinal thickness (CRT) and macular volume (MV) were recorded at baseline and monthly to 6 months.

Results: The mean age of the cohort was 64.9 (SD 11.2) years with 64% males and 36% females. 96% had Type 2 and 4% had Type 1 diabetes mellitus. 68% had prior macular laser and 36% had prior panretinal photocoagulation laser. 47(28%) patients had bilateral injections. Mean baseline VA was 56 (SD 15.2) letters, OCT CRT was 449.2µm (SD 134.3) and MV was 10.2 mm3 (SD 2.2).<br /> <br /> The mean change in VA at 6 months was +5.9 letters (SD 11.9). 30% of eyes showed an increase of ≥10 and 19% ≥15 ETDRS letters. The CRT decreased by 112.1um (SD 158.9) and the MV reduced by 1.41mm3 (SD 2.1). The patients received an average of 5.2 (SD 1.2) injections at 6 months.<br /> There were no cases of endophthalmitis following 1159 injections given during the study period.

Conclusions: Despite this patient group only receiving therapy following UK NHS NICE approval of Ranibizumab for DMO, the data suggests that Ranibizumab therapy in a routine clinical care setting can approach the outcomes of landmark clinical trials.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×